Use of GLP-1s, especially semaglutide and liraglutide, may increase risk for nonarteritic anterior ischemic optic neuropathy ...

A recent study shows the use of GLP-1 drugs can increase the risk for optic nerve damage in the first year of treatment, ...

Eli Lilly’s trial evaluating Mounjaro in reducing cardiovascular risk met its endpoint, though missed analyst expectations.

The results of the SURPASS-CVOT trial showed that dual GLP-1/GIP agonist Mounjaro (tirzepatide) was as effective as Lilly's ...

British Columbia's Health Ministry is limiting the sales of two more diabetes drugs to curb their off-label use for weight ...

Anti-obesity medications can significantly raise testosterone levels and improve health outcomes for men with obesity or type 2 diabetes, according to a new study being presented Monday at ENDO 2025, ...

British Columbia's Ministry of Health is limiting the sales of two more diabetes drugs to curb their off-label use for weight loss and preserve supply for people who are diabetic.

Wegovy, India’s first injectable semaglutide for chronic weight management, recorded Rs 2.54 crore in sales in June ...